Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Prism Pharma Co., Ltd.
Sponsor:
Collaborator:
inVentiv Health Clinical
Information provided by (Responsible Party):
Prism Pharma Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01606579
First received: May 16, 2012
Last updated: October 28, 2014
Last verified: October 2014

May 16, 2012
October 28, 2014
July 2012
May 2015   (final data collection date for primary outcome measure)
DLT (Dose Limiting Toxicity) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Observance of 1 DLT in first 3 patients during 3+3 phase will result in the enrollment of an additional 3 patients.

Observance of 2+ DLTs in 6 patients during 3+3 phase will result in the next lower dose being expanded.

Observance of DLTs in 33% of patients in 10 patient MTD expansion will result in the next lower dose being expanded.

MTD will only be established in a dose level where 0/3 pts or 1/6 pts have a DLT observed in first 2 cycles of therapy.

Two types of DLTs will be observed: non-hematologic and hematologic.

Same as current
Complete list of historical versions of study NCT01606579 on ClinicalTrials.gov Archive Site
Preliminary Efficacy Endpoints [ Time Frame: 1 year ] [ Designated as safety issue: No ]
The preliminary efficacy endpoints will be changes in the response assessment according to International Working Group Response Criteria for Acute Myeloid Leukemia (AML), European LeukemiaNet Response Criteria for Chronic Myeloid Leukemia (CML), International Working Group Response Criteria for Myelodysplastic Syndromes (MDS) and International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia
Same as current
Not Provided
Not Provided
 
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
An Open-Label, Dose-Escalation Phase I/II Study of PRI-724 for Patients With Advanced Myeloid Malignancies

PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced myeloid malignancies. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and spread (metastasize).

PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced myeloid malignancies. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and spread (metastasize).

Purpose:

  • To test the safety of PRI-724 when taken intravenously (through the vein).
  • To observe whether PRI-724 can slow or stop the progression of leukemia.
  • To find the Maximum Tolerated Dose (highest safe dose) in the first two parts of the study.
  • To find the dose of PRI-724 that should be used in the third part of the study and possible future clinical trials that will study effectiveness and additional safety.
  • To test the safety of combining PRI-724 with an approved cancer drug called dasatinib in treating chronic myeloid leukemia (CML).
  • To evaluate whether the combination of PRI-724 with the approved cancer drug dasatinib slows or stops the progression of chronic myeloid leukemia (CML).
  • To test the safety of combining PRI-724 with an approved cancer drug called Cytarabine in treating acute myelogenous leukemia (AML).
  • To evaluate whether the combination of PRI-724 with the approved cancer drug Cytarabine slows or stops the progression of acute myelogenous leukemia (AML).
  • To measure how much PRI-724 appears and remains in the blood after infusion.
  • To measure several signals called biomarkers associated with cancer in the blood to see if PRI-724 affects those signals.

Study Design:

This will be a single center, open-label escalating-dose cohort study with 3 parts: Part I during which the MTD will be determined in acute group patients; Part II during which the MTD will be determined in non-acute group patients; and Part III during which safety and tolerability of escalating doses of PRI-724 will be assessed in combination with dasatinib for CML patients or low dose ara-C therapy for AML patients ≥ 65 years of age.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Acute Myeloid Leukemia
  • Chronic Myeloid Leukemia
  • Drug: PRI-724
    PRI-724
  • Drug: PRI-724
    PRI-724 in combination with dasatinib
  • Drug: PRI-724
    PRI-724 in combination with low dose ara-C therapy
  • Experimental: Part I
    Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Acute Group patients. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
    Intervention: Drug: PRI-724
  • Experimental: Part II
    Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Non-Acute Group patients. Dosing will begin 2 dose levels below the Part I MTD. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
    Intervention: Drug: PRI-724
  • Experimental: Part III Arm A

    Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.

    Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with low dose ara-C therapy (20 mg SC BID × 10d q 28d) for AML patients ≥ 65 years of age.

    Intervention: Drug: PRI-724
  • Experimental: Part III Arm B

    Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.

    Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with dasatinib (140 mg PO daily) to Acute Group patients with CML-AP or BC.

    Intervention: Drug: PRI-724
  • Experimental: Part III Arm C

    Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.

    Escalating doses of PRI-724, beginning 1 dose level below the Part II MTD will be administered in combination with dasatinib (100 mg PO daily) to Non-Acute Group patients with CML-CP.

    Intervention: Drug: PRI-724
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
104
July 2015
May 2015   (final data collection date for primary outcome measure)

Inclusion Criteria

  1. Patients 18 years or older
  2. Part I: Patients with one of the following histologically- or cytologically-proven conditions: relapsed/refractory AML, relapsed/refractory MDS, or advanced CML in AP or BP (i.e., Acute Group patients).
  3. Part II: Patients with one of the following documented conditions: CML in CP that is Philadelphia chromosome (Ph)-positive (by cytogenetics) or BCR-ABL1-positive by fluorescent in situ hybridization [FISH], or PCR), as well as resistant to at least 2 FDA-approved tyrosine kinase inhibitors (TKIs); or a myeloproliferative neoplasia which includes: PMF and myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET) myelofibrosis (MF) (with intermediate-1, intermediate-2 or high risk disease according to the International Working Group [IWG] prognostic scoring system) (i.e., Non-Acute Group patients).
  4. Part III:

    • Arm A: Patients with AML who are 65 years of age or older with refractory or relapsed disease, or who have not received prior therapy but are not eligible to receive intensive frontline chemotherapy (i.e., Acute Group patients);
    • Arm B: Patients with CML in AP or BP, either newly diagnosed or failing TKI therapy (i.e., Acute Group patients);
    • Arm C: Patients with CML in CP after failure of 2 FDA-approved TKIs (i.e., Non-Acute group patients)
  5. Performance status 0-2 of the Eastern Cooperative Oncology Group (ECOG) scale
  6. Patients must have been off all prior therapy for leukemia except hydroxyurea for 1 week prior to entering this study and recovered from the toxic effects of that therapy
  7. Adequate organ function as defined by:

    • Serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance ≥60 mL/min
    • Total bilirubin ≤2 x ULN (≤5 x ULN if considered due to Gilbert's syndrome or hemolysis)
    • Alanine aminotransferase (ALT) ≤3xULN
  8. Patients must sign an informed consent indicating that they are aware of the investigational nature of this study.
  9. Women of childbearing potential and men should practice effective methods of contraception. Women of childbearing potential should have a negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin within 7 days prior to the start of PRI 724.

Exclusion Criteria

  1. Patients receiving any other investigational agents
  2. Patients who are pregnant or breast-feeding
  3. Known hypersensitivity to any of the components of PRI-724
  4. Pretreatment QTcF interval >470 msec (females) or >450 msec (males)
  5. Known active hepatitis B, hepatitis C
  6. Serious uncontrolled medical disorder or active systemic infection or current unstable or decompensated medical condition, which makes it undesirable or unsafe for the patient to participate in the study including: New York Heart Association (NYHA) Class 3 or 4, myocardial infarction within 3 months, uncontrolled angina within 3 months, history of clinically significant ventricular arrhythmia, diabetes mellitus with ketoacidosis, or chronic obstructive pulmonary disease (COPD) requiring hospitalization in 6 months prior to the start of treatment with PRI-724.
  7. Any other condition, including mental illness or substance abuse deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate, and participate in the study
  8. Patients on full dose anticoagulants or any dose of warfarin; patients on prophylactic dose of low-molecular weight or unfractionated heparin are allowed.
  9. Patients who have demonstrated intolerance to dasatinib 100 mg daily will not be eligible for Part III/Arm B or C of the study.
Both
18 Years and older
No
Contact: Andria E Cress, BA (773) 632-1750 andria.cress@inventivhealth.com
Contact: Craig Schleyer (773)632-1785 craig.schleyer@inventivhealth.com
United States
 
NCT01606579
PRI-724-201
No
Prism Pharma Co., Ltd.
Prism Pharma Co., Ltd.
inVentiv Health Clinical
Principal Investigator: Jorge Cortes, MD M.D. Anderson Cancer Center
Prism Pharma Co., Ltd.
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP